Abstract:2405 Lymph node metastases remain a long-term problem in the treatment of head and neck sqaumous cell carcinoma (HNSCC). In an effort to understand the biology of metastasis of HNSCC and to develop effective therapeutic regimens against metastatic HNSCC, we established highly metastatic HNSCC cell lines through in vivo selection (Zhang et al, Clin Exp Metastasis, 2006). Using gene array and Western blot analysis, we found that highly metastatic HNSCC cell lines exhibit increased levels of death receptor 5 (DR5), Fas-associated death domain (FADD), caspase-8, caspase-9, and the short form of c-FLIP (FLIPS). Moreover, these metastatic cell lines had decreased levels of the long form of c-FLIP (FLIPL) and undetectable levels of TRAIL. Accordingly, the metastatic HNSCC cell lines are relatively more sensitive than their parental non-metastatic cell line to exogenous TRAIL treatment. These results suggest that metastatic HNSCC cells retain the capacity to undergo death receptor-mediated apoptosis. Perifosine is the first oral alkylphospholipid with Akt-inhibitory activity and is being tested in phase II cancer clinical trials. We found that perifosine further upregulated DR5 expression and reduced c-FLIP levels in the metastatic HNSCC cell lines. Interestingly, the metastatic HNSCC cell lines were much more sensitive than their parental cell line to perifosine-induced apoptosis. Moreover, the combination of perifosine and TRAIL augmented induction of apoptosis in the metastatic HNSCC cells. Collectively, these data suggest that targeting activation of TRAIL/death receptor-mediated apoptosis by the combination of perifosine and TRAIL has therapeutic potential against metastatic HNSCC, thus warranting in vivo evaluation of the efficacy of the combination of perifosine and TRAIL for treatment of metastatic HNSCC. (Supported in part by GCC Distinguished Cancer Scholar award and DOD grant DAMD17-01-1-0689-BESCT)

Peritoneal Gene Transfection of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand for Tumor Surveillance and Prophylaxis

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Dual-targeting Nanoparticles with Excellent Gene Transfection Efficiency for Gene Therapy of Peritoneal Metastasis of Colorectal Cancer.

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Therapeutic potential of the Akt inhibitor perifosine in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for metastatic head and neck cancer.

Enzyme-responsive Charge-Reversal Polymer Mediated Effective Gene Therapy for Intraperitoneal Tumors

New Path to Treating Pancreatic Cancer: TRAIL Gene Delivery Targeting the Fibroblast-Enriched Tumor Microenvironment

Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis

Suppression of Teratocarcinoma Growth by Soluble Trail Gene Expression Driven by the Progression-Elevated Gene-3 Promoter

Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice.

Tumor micro-environment induced TRAIL secretion from engineered macrophages for anti-tumor therapy

Targeting non-coding RNAs as a promising biomarker in peritoneal metastasis: Background, mechanism, and therapeutic approach

Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein

Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers